Collaboration Agreements - Additional Information (Details)						1 Months Ended	12 Months Ended
	Dec. 03, 2021 USD ($)	Oct. 01, 2021	Jun. 30, 2021 USD ($)	Jun. 17, 2020 USD ($) Target	Jan. 02, 2019 USD ($) Candidate Target Obligation	Apr. 30, 2021 Target	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 23, 2020 USD ($)
Collaboration Agreements [Line Items]
Number of performance obligations | Obligation					8
Total collaboration revenue							$ 22,935,000	$ 2,915,000
Revenue recognized was previously classified as, Deferred revenue, net of current portion							19,048,000	641,000
Deferred revenue							43,649,000
Up-front and non-refundable cash payments received							66,000,000.0
Deferred revenue							12,963,000	5,281,000
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited
Collaboration Agreements [Line Items]
Number of oncogene targets | Target					5
Number of targets | Target					4
Number of oncogene targets discontinue work | Target						1
Number of clinical trial candidates | Candidate					2
Number of remaining candidates | Candidate					3
Additional milestone payment related to regulatory approval of product					$ 20,000,000.0
Up-front payment					56,000,000.0
Preclinical development milestone payments eligible to receive					20,000,000.0
Collaboration target payment receivable due upon second initiation					10,000,000.0
Milestone payments eligible to receive					$ 200,000,000.0
Notice period for termination of agreement					180 days
Collaboration arrangement transaction price measured based on non-refundable and non creditable up-front payment							56,000,000.0
Variable consideration payable included in transaction price at inception							0
Remaining consideration comprised solely of transaction price									$ 55,000,000.0
Changes in estimate of variable consideration							0
Remaining deferred revenue recognized							10,900,000
Total collaboration revenue			$ 2,800,000				11,300,000	600,000
Deferred revenue							43,700,000	55,000,000.0
Deferred revenue							12,600,000
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Research and Development
Collaboration Agreements [Line Items]
Cost associated with obligations under arrangement							2,500,000	3,300,000
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Development and Commercialization License and Associated Research Services | ASU 2014-09
Collaboration Agreements [Line Items]
Option to include additional target additional cost					$ 0
Replacement target additional cost					0
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Research Services | ASU 2014-09
Collaboration Agreements [Line Items]
Option to request additional research program additional cost					0
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Non-GLP Toxicology Studies | ASU 2014-09
Collaboration Agreements [Line Items]
Per backup development candidate cost upon exercise					$ 0
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | License and Services
Collaboration Agreements [Line Items]
Performance obligation unsatisfied							39,600,000	50,900,000
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | All Other Services
Collaboration Agreements [Line Items]
Performance obligation unsatisfied							4,100,000	4,100,000
Sarepta Research Agreement
Collaboration Agreements [Line Items]
Up-front payment				$ 7,000,000.0
Milestone payments eligible to receive				$ 192,500,000
Total collaboration revenue	$ 7,000,000.0						11,600,000	2,300,000
Revenue recognized was previously classified as, Deferred revenue, net of current portion	$ 7,000,000.0
Deferred revenue							0	7,700,000
Research agreement period		2 years		2 years
Number of agreed targets | Target				5
Effective contract termination date		Dec. 03, 2021
Term of option exercise				Jun. 17, 2022
Extended term of option exercise				Dec. 17, 2022
Up-front and non-refundable cash payments received				$ 10,000,000.0
Up-front research services prepayment				3,000,000.0
Collaboration arrangement obligated to remit option exercise payment				12,500,000
Collaboration arrangement obligated options exercised				62,500,000
Sarepta Research Agreement | Research and Development
Collaboration Agreements [Line Items]
Cost associated with obligations under arrangement							$ 4,600,000	2,300,000
Sarepta Research Agreement | ASU 2014-09
Collaboration Agreements [Line Items]
Up-front payment				7,000,000.0
Up-front research services prepayment				3,000,000.0
Aggregate transaction price				18,000,000.0
Estimation of cost reimbursements				$ 8,000,000.0
Sarepta Research Agreement | All Other Services
Collaboration Agreements [Line Items]
Performance obligation unsatisfied								7,000,000.0
Sarepta Research Agreement | Research License and Services
Collaboration Agreements [Line Items]
Performance obligation unsatisfied								$ 8,700,000